论文部分内容阅读
为研究多发性骨髓瘤（ＭＭ）患者血清骨胶原代谢产物浓度与白细胞介素６（ＩＬ－６）活性的相关性，运用放射免疫分析法检测５６例ＭＭ患者血清Ｉ型胶原代谢产物Ｉ型胶原羧基远端交联肽（ＩＣＴＰ）和Ｉ型原胶原羧基末端肽（ＰＩＣＰ）浓度，前者反映Ｉ型胶原的分解代谢率，后者反映其合成代谢率。结果表明，ＭＭ患者血清ＩＣＴＰ和ＰＩＣＰ浓度均较正常对照组明显增高（Ｐ＜０．０１）。其中血清ＩＣＴＰ浓度随病程进展和溶骨病灶数增多而升高。血清ＰＩＣＰ浓度与病程进展及溶骨病灶多少无明显关系。此外，血清ＩＣＴＰ和ＰＩＣＰ浓度与Ｍ蛋白类别无关。结果提示血清ＩＣＴＰ浓度是评估ＭＭ溶骨损害的一项良好的血清学指标。血清ＰＩＣＰ浓度改变可能是ＭＭ骨胶原合成代偿性增加的结果。结果还表明，患者血清ＩＬ－６活性与ＩＣＴＰ浓度有明显正相关（ｒ＝０．６１０，Ｐ＜０．０１），从而进一步证实在ＭＭ中有破骨细胞激活因子活性。
To investigate the correlation between serum collagen metabolite concentration and interleukin-6 (IL-6) activity in patients with multiple myeloma (MM), radioimmunoassay was used to detect type I collagen metabolite type I collagen in 56 patients with MM. The concentration of carboxyl distal peptide (ICTP) and type I procollagen carboxy terminal peptide (PICP), the former reflects the catabolic rate of type I collagen, and the latter reflects the anabolic rate. The results showed that the serum concentrations of ICTP and PICP in MM patients were significantly higher than those in normal controls (P<0.01). The serum ICTP concentration increased with the progression of the disease and the number of osteolytic lesions. Serum PICP concentrations did not significantly correlate with disease progression and osteolytic lesions. In addition, serum ICTP and PICP concentrations are independent of the M protein class. The results suggest that serum ICTP concentration is a good serological marker for evaluating MM osteolytic lesions. Changes in serum PICP concentrations may be the result of a compensatory increase in MM collagen synthesis. The results also showed that there was a positive correlation between serum IL-6 activity and ICTP concentration (r=0.610, P<0.01), which further confirmed the activity of osteoclast activating factor in MM.